Table 2. Characteristics of patients who experienced proteinuria exacerbation in two combined seasonal periods.
Spring and summer (n = 14) |
Autumn and winter (n = 36) |
P value | |
---|---|---|---|
Characteristic at kidney biopsy | |||
Hypertension | 3 (21.4) | 16 (44.4) | 0.20 |
BMI | 21.5 ± 2.80 | 21.6 ± 3.39 | 0.92 |
Serum IgA, mg/dL | 324.5 [241.8–486.8] | 313.0 [261.5–364.0] | 0.67 |
IgA/C3 ratio | 3.53 [2.58–4.78] | 3.13 [2.56–3.90] | 0.49 |
JHC Ⅰ / Ⅱ+Ⅲ+Ⅳ | 9(64.3)/5(35.7) | 16(47.1)/18(52.9) | 0.35 |
Characteristic at proteinuria exacerbation | |||
Age, years | 40.9 ± 15.2 | 40.8 ± 13.3 | 0.99 |
Male/Female | 3/11 (21.4/78.6) | 13/23 (36.1/63.9) | 0.50 |
Antecedent infection | 4 (28.6) | 6 (16.7) | 0.44 |
Usage of RASB | 6 (42.9) | 24 (66.7) | 0.20 |
Usage of oral PSL | 2 (14.3) | 7 (19.4) | 1 |
SBP, mmHg | 116.6 ± 19.9 | 118.8 ± 14.9 | 0.68 |
DBP, mmHg | 74.6 ± 10.6 | 73.5 ± 14.1 | 0.79 |
MAP, mmHg | 88.6 ± 12.7 | 88.6 ± 13.4 | 0.99 |
TA-MAP, mmHg | 84.7 ± 9.40 | 85.2 ± 9.53 | 0.88 |
eGFR, ml/min/1.73m2 | 70.7 ± 20.3 | 70.0 ± 21.8 | 0.92 |
UPE, g/gCr | 0.93 [0.86–1.12] | 1.03 [0.84–1.22] | 0.75 |
TA-P, g/gCr | 0.52 [0.37–0.70] | 0.49 [0.38–0.75] | 0.90 |
Remission duration, month | 22.1 [9.84–48.9] | 26.1 [7.59–34.3] | 0.66 |
U-RBC≥ 5/HPF | 8 [57.1] | 16 [44.4] | 0.53 |
Mean outdoor temperature, °C | 16.0 ± 8.44 | 9.31 ± 6.64 | 0.005* |
Mean humidity, % | 67.9 ± 12.9 | 63.3 ± 12.2 | 0.24 |
Intensive therapy | 7 (50.0) | 14 (38.9) | 0.53 |
Second remission | 6 (42.9) | 28 (77.8) | 0.040* |
Values are presented as mean (± SD), median [IQR], and Numbers (%). Abbreviations: BMI, body mass index; JHC, Japanese histological classification; RASBs, renin-angiotensin system blockers; PSL, prednisolone; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; TA-MAP, time-averaged arterial pressure; eGFR, estimated glomerular filtration rate; UPE, urinary protein excretion; TA-P, time-averaged proteinuria; U-RBC, urinary red blood cell sediments; HPF, high power field.
* p < 0.05